Bénéfice-risque : le rapport introuvableBERGMANN, Jean-Francois.Concours médical (Paris). 2005, Vol 127, Num 28, pp 1584-1586, issn 0010-5309, 3 p.Article

Quel rapport bénéfices/risques pour les nouveaux anticoagulants ? : Fibrillation AtrialeSELLAL, Jean-Marc; ALIOT, Etienne.Concours médical (Paris). 2012, Vol 134, Num 8, pp 610-611, issn 0010-5309, 2 p.Article

Balancing potential risks and benefits of using confidential dataDAVIES, Christina; COLLINS, Rory.BMJ. British medical journal (International ed.). 2006, Vol 333, Num 7563, pp 349-351, issn 0959-8146, 3 p.Article

Uncertain compassion in using a drug before the risks and benefits are knownNARAYANAN, Raja; KUPPERMANN, Baruch D.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1032-1034, issn 0003-9950, 3 p.Article

A Concise Display of Multiple End Points for Benefit-Risk AssessmentLEVITAN, B.Clinical pharmacology and therapeutics. 2011, Vol 89, Num 1, pp 56-59, issn 0009-9236, 4 p.Article

A Comprehensive Approach to Benefit―Risk Assessment in Drug DevelopmentSARAC, Sinan B; RASMUSSEN, Christian H; RASMUSSEN, Morten A et al.Basic & clinical pharmacology & toxicology (Print). 2012, Vol 111, Num 1, pp 65-72, issn 1742-7835, 8 p.Article

Un rapport bénéfice/risque indiscutablement élevé : BiothérapiesTRON, Francois.Concours médical (Paris). 2008, Vol 130, Num 9, pp 453-455, issn 0010-5309, 3 p.Article

Bénéfices et risques de la chirurgie bariatriqueDETRY, R.Louvain médical. 2007, Vol 126, Num 5, pp 160-162, issn 0024-6956, 3 p.Conference Paper

HRT : a reappraisal of the risks and benefitsMACLENNAN, Alastair H.Medical journal of Australia. 2007, Vol 186, Num 12, pp 643-646, issn 0025-729X, 4 p.Article

Pour mieux soigner: des médicaments à écarterLa Revue Prescrire. 2013, Vol 33, Num 352, pp 138-142, issn 0247-7750, 5 p.Article

Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT)ROGAN, Walter J; AIMIN CHEN.Lancet (British edition). 2005, Vol 366, Num 9487, pp 763-773, issn 0140-6736, 11 p.Article

Improving the Decision-Making Process for Nonprescription Drugs: A Frameworkfor Benefit-Risk AssessmentBRASS, E. P; LOFSTEDT, R; RENN, O et al.Clinical pharmacology and therapeutics. 2011, Vol 90, Num 6, pp 791-803, issn 0009-9236, 13 p.Article

Drug prophyaxis in general medical patients: does usage reflect the benefits and risks?HERZIG, Shoshana; ROTHBERG, Michael.BMJ (Overseas and retired doctors ed.). 2012, Vol 344, Num 7860, pp 21-23, issn 1759-2151, 3 p.Article

Using a drug before the risks and benefits are known from a phase 3 clinical trial : Thoughts on compassionMILLER, Joan W.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1029-1031, issn 0003-9950, 3 p.Article

Carotid artery stents for blunt cerebrovascular injury : Risks exceed benefits. DiscussionCOTHREN, C. Clay; MOORE, Ernest E; RAY, Charles E et al.Archives of surgery (Chicago, IL. 1960). 2005, Vol 140, Num 5, pp 480-486, issn 0004-0010, 7 p.Article

Si j'étais plus mince... ou les effets de la fée Rapidominceur ! = If I were slimmer... or the effect of the Fastslim Fairy!LEMOINE, C.Obésité. 2008, Vol 3, Num 2, pp 89-91, issn 1951-5995, 3 p.Article

Current assessment of risk-benefit by regulators : Is it time to introduce decision analyses?HUGHES, D. A; BAYOUMI, A. M; PIRMOHAMED, M et al.Clinical pharmacology and therapeutics. 2007, Vol 82, Num 2, pp 123-127, issn 0009-9236, 5 p.Article

Cesarean delivery and the risk-benefit calculusECKER, Jeffrey L; FRIGOLETTO, Fredric D.The New England journal of medicine. 2007, Vol 356, Num 9, pp 885-888, issn 0028-4793, 4 p.Article

A Benefit-Risk Assessment of the Use of Proton Pump Inhibitors in the ElderlyMASCLEE, Gwen M. C; STURKENBOOM, Miriam C. J. M; KUIPERS, Ernst J et al.Drugs & aging. 2014, Vol 31, Num 4, pp 263-282, issn 1170-229X, 20 p.Article

Déterminer la balance bénéfices-risques d'une intervention: pour chaque patientLa Revue Prescrire. 2014, Vol 34, Num 367, pp 381-385, issn 0247-7750, 5 p.Article

Intentional Rechallenge: Does the Benefit Outweigh the Risk?STANULOVIC, Vid; VENEGONI, Mauro; EDWARDS, Brian et al.Drug safety. 2013, Vol 36, Num 3, pp 155-161, issn 0114-5916, 7 p.Article

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering : Benefits versus risksMCKENNEY, James M.The American journal of cardiology. 2005, Vol 96, Num 4, pp 60E-66E, issn 0002-9149, SUPConference Paper

Is Timing Everything? A Meeting Report of the Society for Women's Health Research Roundtable on Menopausal Hormone TherapyDAVIES, Erika; MANGONGI, Ngoda P; CARTER, Christine L et al.Journal of women's health (Larchmont, N.Y. 2002). 2013, Vol 22, Num 4, pp 303-311, issn 1540-9996, 9 p.Article

State of the art in benefit―risk analysis: Economics and Marketing-FinanceKALOGERAS, N; ODEKERKEN-SCHRÖDER, G; TUOMISTO, J. T et al.Food and chemical toxicology. 2012, Vol 50, Num 1, pp 56-66, issn 0278-6915, 11 p.Article

BRAFO tiered approach for benefit―risk assessment of foodsHOEKSTRA, Jeljer; HART, Andy; TORGERSON, Paul R et al.Food and chemical toxicology. 2012, Vol 50, issn 0278-6915, S684-S698, SUP4Article